OnKure Therapeutics (OKUR)
NASDAQ:OKUR
US Market
Holding OKUR?
Track your performance easily

OnKure Therapeutics (OKUR) Income Statement

242 Followers

OnKure Therapeutics Income Statement

Last quarter (Q3 2024), OnKure Therapeutics's total revenue was $―, a decrease of ― from the same quarter last year. In Q3, OnKure Therapeutics's net income was $-3.69M. See OnKure Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
----$ 0.00$ 0.00
Cost of Revenue
------
Gross Profit
------
Operating Expense
$ 41.48M$ 83.05M$ 53.85M$ 39.82M$ 19.55M$ 15.47M
Operating Income
$ -41.48M$ -83.05M$ -53.85M$ -39.82M$ -19.55M$ -15.47M
Net Non Operating Interest Income Expense
----$ 87.00K$ 456.00K
Other Income Expense
$ -4.80M$ -5.67M$ 1.89M$ -48.00K$ 87.00K$ 2.58M
Pretax Income
$ -36.67M$ -77.39M$ -51.95M$ -39.77M$ -19.46M$ -12.44M
Tax Provision
------
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -36.67M$ -77.39M$ -51.95M$ -39.77M$ -19.46M$ -12.44M
Basic EPS
$ -2.08$ -2.52$ -2.12$ -2.19$ -2.50$ -1.60
Diluted EPS
$ -2.08$ -2.52$ -2.12$ -2.19$ -2.50$ -1.60
Basic Average Shares
$ 103.99M$ 30.68M$ 24.50M$ 18.14M$ 7.79M$ 7.79M
Diluted Average Shares
$ 103.99M$ 30.68M$ 24.50M$ 18.14M$ 7.79M$ 7.79M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 41.48M$ 83.05M$ 53.85M$ 39.82M$ 19.55M$ 15.47M
Net Income From Continuing And Discontinued Operation
$ -36.67M$ -77.39M$ -51.95M$ -39.77M$ -19.46M$ -12.44M
Normalized Income
$ -8.96M--$ -31.42M$ -19.46M$ -12.44M
Interest Expense
------
EBIT
$ -39.51M$ -77.39M$ -51.95M$ -39.77M$ -19.55M$ -15.47M
EBITDA
$ -38.52M$ -77.22M$ -51.87M$ -39.52M$ -19.52M$ -15.44M
Currency in USD

OnKure Therapeutics Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis